MAP3K1-targeting therapeutic artificial miRNA suppresses the growth and invasion of breast cancer in vivo and in vitro

Recent investigations have highlighted that therapeutic artificial microRNAs could be promising candidates for cancer therapy through the modulation of tumor promoter or suppressor. MEK kinase 1 (MEKK1) is expressed by mitogen-activated kinase kinase kinase 1 (MAP3K1), an important kinase that links Ras activation to MAPK signaling. In the present study, we showed that synthetic MAP3K1-targeting artificial miRNA may provide considerable beneficial effects in the prevention of breast cancer growth and metastasis. We showed that MEKK1 was highly expressed in human breast cancer specimens, compared with adjacent normal tissues. Using a miRNA-expressing lentivirus system, we delivered a artificial miRNA (Map3k1 amiRNA) that targets MAP3K1 into 4T1 breast cancer cells and investigated the impact of MAP3K1-targeting miRNA on the growth and invasive behavior of breast cancer in vitro and in vivo. We found that overexpression of Map3k1 amiRNA led to impaired activities of p-ERK and p-p38. In addition, Map3k1 amiRNA induced marked proliferative impairment and invasive attenuation in breast cancer cells. However, Map3k1 amiRNA did not have evident influence on the apoptotic response of 4T1 cells. Moreover, using in vivo nude mice model, we identified that Map3k1 amiRNA attenuated tumor growth and lung metastasis of breast cancer cells. Taken together, our findings explicitly indicated that MEKK1 exerted important oncogenic property in breast cancer development, and MAP3K1-targeting artificial miRNA may provide promising therapeutic effects in the treatment of breast cancer.

[1]  S. Jang,et al.  Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers , 2007, Breast Cancer Research and Treatment.

[2]  Zheng Bao,et al.  Establishment and characterization of MTDH knockdown by artificial MicroRNA interference - functions as a potential tumor suppressor in breast cancer. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[3]  Hiromu Suzuki,et al.  A Single Recombinant Adenovirus Expressing p53 and p21-targeting Artificial microRNAs Efficiently Induces Apoptosis in Human Cancer Cells , 2009, Clinical Cancer Research.

[4]  Brian L. Gilmore,et al.  Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi , 2008, Proceedings of the National Academy of Sciences.

[5]  G. Johnson,et al.  Direct Interaction between Ras and the Kinase Domain of Mitogen-activated Protein Kinase Kinase Kinase (MEKK1) (*) , 1995, The Journal of Biological Chemistry.

[6]  A. Winter-Vann,et al.  MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer , 2006, Oncogene.

[7]  Kevin W. Eliceiri,et al.  The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis , 2013, Nature Cell Biology.

[8]  Debajit K. Biswas,et al.  NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis , 2004 .

[9]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[10]  Serge Lemay,et al.  The p38 MAPK Pathway Is Required for Cell Growth Inhibition of Human Breast Cancer Cells in Response to Activin* , 2001, The Journal of Biological Chemistry.

[11]  Z. Cai,et al.  Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells , 2012, PloS one.

[12]  H. Shirasawa,et al.  Dominant negative MEKK1 inhibits survival of pancreatic cancer cells , 2002, Oncogene.

[13]  J. Lu,et al.  Controlled delivery of antisense oligonucleotides: a brief review of current strategies , 2009, Expert opinion on drug delivery.

[14]  C. Croce,et al.  microRNAs: Master regulators as potential therapeutics in cancer. , 2011, Annual review of pharmacology and toxicology.

[15]  L. Zon,et al.  Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1 , 1994, Nature.

[16]  Andrei V Bakin,et al.  Integrin β5 contributes to the tumorigenic potential of breast cancer cells through Src-FAK and MEK-ERK signaling pathways , 2012, Oncogene.

[17]  R. Seger,et al.  The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions , 2006, Growth factors.

[18]  S. Hilsenbeck,et al.  Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. , 2009, Cancer research.

[19]  Kathryn A. O’Donnell,et al.  Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.

[20]  Sankar Ghosh,et al.  NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Cai,et al.  Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis. , 2006, Biochemical and biophysical research communications.

[22]  J. Nemunaitis,et al.  Small interfering RNA for experimental cancer therapy. , 2005, Current opinion in molecular therapeutics.

[23]  T. Maniatis,et al.  MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Miska,et al.  How microRNAs control cell division, differentiation and death. , 2005, Current opinion in genetics & development.

[25]  Thomas Tuschl,et al.  MicroRNAs in human cancer. , 2013, Advances in experimental medicine and biology.

[26]  H. Pehamberger,et al.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. , 2004, The Journal of clinical investigation.

[27]  K. Nakayama,et al.  Estrogens Down-regulate p27Kip1 in Breast Cancer Cells through Skp2 and through Nuclear Export Mediated by the ERK Pathway* , 2003, Journal of Biological Chemistry.

[28]  H. Shim,et al.  Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. , 2007, Biochemical and biophysical research communications.

[29]  Xiaoyan Liu,et al.  An Artificial miRNA against HPSE Suppresses Melanoma Invasion Properties, Correlating with a Down-Regulation of Chemokines and MAPK Phosphorylation , 2012, PloS one.

[30]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[31]  Jack Cuzick,et al.  Preventive therapy for breast cancer: a consensus statement. , 2011, The Lancet. Oncology.

[32]  Xiaoguang Chen,et al.  Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells , 2009, Journal of Cancer Research and Clinical Oncology.

[33]  S. Elledge,et al.  A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Mari C Sogayar,et al.  TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells , 2011, BMC Cancer.

[35]  Andreas Sommer,et al.  NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .

[36]  G. Kundu,et al.  Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. , 2007, Oncology reports.

[37]  G. Devi,et al.  siRNA-based approaches in cancer therapy , 2006, Cancer Gene Therapy.

[38]  P. Poulikakos,et al.  Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.

[39]  Eun-Jung Lee,et al.  p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. , 2003, Cancer research.

[40]  Shuang Huang,et al.  Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway , 2004, Cancer Research.